Pritelivir | HSV helicase-primase inhibitor

Pritelivir chemical structure

Available Options

Size:PriceQuantity 
10 mg$50.00
50 mg$150.00
Request Quote / Bulk / Custom Size
Product Inquiry

Pritelivir (348086-71-5) is a potent non-nucleosidic inhibitor of the herpes simplex virus helicase-primase (IC50 = 20 nM HSV1/2).1 Active against acyclovir-resistant HSV. Pritelivir showed superior efficacy against HSV in vivo compared to acyclovir, famiciclovir, ganciclovir, and valacyclovir.2 It greatly reduced the formation of ß-amyloid and abnormal tau in HSV1 infected cultured cells.3

References/Citations:

  1. Kleyman et al. (2002), New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease; Nat. Med. 8 392
  2. Betz et al. (2002), Potent In Vivo Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293; Antimicrob. Agents Chemother. 46 1766
  3. Wozniak et al. (2013), The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer’s disease-related molecules induced by herpes simplex virus type 1; Antiviral Res. 99 401
348086-71-5, BAY 57-1293, helicase inhibitor, helicase-primase inhibitor, pritelivir, Pritelivir supplier
Alternate Name:
BAY 57-1293

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Pritelivir (348086-71-5) is a potent non-nucleosidic inhibitor of the herpes simplex virus helicase-primase (IC50 = 20 nM HSV1/2).1 Active against acyclovir-resistant HSV. Pritelivir showed superior efficacy against HSV in vivo compared to acyclovir, famiciclovir, ganciclovir, and valacyclovir.2 It greatly reduced the formation of ß-amyloid and abnormal tau in HSV1 infected cultured cells.3

References/Citations:

  1. Kleyman et al. (2002), New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease; Nat. Med. 8 392
  2. Betz et al. (2002), Potent In Vivo Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293; Antimicrob. Agents Chemother. 46 1766
  3. Wozniak et al. (2013), The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer’s disease-related molecules induced by herpes simplex virus type 1; Antiviral Res. 99 401